Bill > SB00191

This bill amends existing law to expand access to and extend a psychedelic-assisted therapy pilot program, which will now be administered by a medical school in the state and will provide qualified patients with therapy using MDMA (a synthetic psychoactive drug also known as ecstasy or molly) or psilocybin (a naturally occurring substance found in some mushrooms). A qualified patient is defined as an individual who is at least eighteen years old and meets specific clinical eligibility criteria set by the medical school's institutional review board, in addition to being a resident of the state who is a veteran, a retired first responder, or a direct care healthcare worker. The program will offer this therapy as part of a research initiative approved by the federal Food and Drug Administration, and this change will take effect on July 1, 2026.

Health and Social Services

Public Health Committee (Joint)

https://www.cga.ct.gov/asp/cgabillstatus/cgabillstatus.asp?selBillType=Bill&bill_num=SB00191&which_year=2026